Investor Presentaiton

iberdomide (CELMOD) Indication Phase/Study # of Patients 2L+ MM Phase III EXCALIBER - Oncology Hematology Cell Therapy Immunology Cardiovascular Post-Transplant Maintenance NDMM Phase III EXCALIBER-Maintenance Design Endpoints Status CT Identifier • N = 864 Iberdomide 1.0, 1.3,1.6 mg + daratumumab 1800 mg + dex 40 mg (iberDd) Daratumumab 1800 mg + bortezomib 1.3 mg/m2a + dex 20 mga - (DVD) Primary: PFS Key secondary: OS Recruiting Projected data readout 2026 NCT04975997 N = 1,216 Iberdomide Dose 0.75, 1.0, 1.3 mg Lenalidomide 10 mg Primary: PFS Key Secondary: MRD, OS Recruiting Projected data readout 2029 NCT05827016 ll Bristol Myers Squibb Q3 2023 Results aBIW dosing Not for Product Promotional Use 40

View entire presentation